Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRITAM vs FINTEPLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
Adjunctive therapy for partial-onset seizures,Myoclonic seizures in JME,Primary generalized tonic-clonic seizures
Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older,Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older
SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
Terminal half-life: 6–8 hours; clinical context: requires twice-daily dosing for stable serum concentrations
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
Hydrolysis by esterases in blood and tissues to carboxylic acid metabolite (ucb L057); not CYP450 dependent.
Fenfluramine is primarily metabolized by CYP1A2, CYP2B6, and CYP2D6 to its active metabolite norfenfluramine. Norfenfluramine is further metabolized by CYP2D6 and other enzymes.
Renal: 66% unchanged; hepatic metabolism: 24% (inactive metabolites); fecal: negligible (<1%)
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
<10% bound; primarily to albumin (minimal binding)
Approximately 55% bound to plasma proteins, primarily albumin.
0.7–1.1 L/kg; approximates total body water, indicating extensive distribution into tissues
Apparent volume of distribution (Vd/F) approximately 2.5–3.5 L/kg, suggesting extensive extravascular distribution.
Oral immediate-release: 100%; oral extended-release: approximately 100% relative to immediate-release
Oral bioavailability approximately 80% (relatively high first-pass metabolism: moderate).
Cr Cl >80 m L/min: 500-1500 mg BID (IR) or 1000-2000 mg once daily (XR); Cr Cl 50-80: 500-1000 mg BID (IR) or 1000-2000 mg once daily (XR); Cr Cl 30-50: 250-750 mg BID (IR) or 500-1500 mg once daily (XR); Cr Cl <30: 250-500 mg BID (IR) or 500-1000 mg once daily (XR); ESRD on dialysis: 500-1000 mg once daily (IR) with supplemental dose after dialysis.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
Mild to moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required; severe hepatic impairment (Child-Pugh C): use with caution; no specific dose reduction recommended, but monitor for adverse effects.
Mild hepatic impairment (Child-Pugh A): maximum dose 11 mg/day. Moderate to severe (Child-Pugh B or C): not recommended.
For immediate-release: age 1 month to <6 months: 7 mg/kg/dose BID initially, titrate to 21 mg/kg/dose BID; age 6 months to <4 years: 10 mg/kg/dose BID initially, titrate to 25 mg/kg/dose BID; age 4 to <16 years: 10 mg/kg/dose BID initially, titrate up to 30 mg/kg/dose BID (max 1500 mg/day). For extended-release: only for ≥12 years: 1000 mg once daily initially, titrate to 2000 mg once daily.
For patients weighing 10-50 kg: initial 0.05 mg/kg twice daily; titrated to 0.1 mg/kg twice daily (target), may increase to 0.2 mg/kg twice daily (max). For patients weighing ≥50 kg: same as adult dosing (max 16 mg/day). Not established for weight <10 kg.
Consider age-related renal impairment; adjust dose based on Cr Cl per renal adjustment. Start at lower end of dosing range; monitor for sedation, dizziness, and falls.
No specific dose adjustment; start at low end of dosing range due to greater frequency of decreased hepatic/renal function and concomitant disease.
No FDA black box warning.
Valvular heart disease and pulmonary arterial hypertension: FINTEPLA is associated with valvular heart disease (e.g., mitral and aortic regurgitation) and pulmonary arterial hypertension. Patients must undergo echocardiography before starting treatment, at 3 months, and every 6-12 months thereafter.
Behavioral abnormalities (psychosis, aggression, suicidal ideation),Somnolence and fatigue,Dermatological reactions (e.g., Stevens-Johnson syndrome),Hematologic abnormalities,Withdrawal seizures on abrupt discontinuation
Valvular heart disease and pulmonary arterial hypertension: monitor with echocardiography,Increased intraocular pressure: caution in patients with glaucoma,Suicidal thoughts and behavior: monitor for worsening depression and suicidality,Dizziness, somnolence, and fatigue: may impair ability to drive or operate machinery,Decreased appetite and weight loss: monitor weight, especially in pediatric patients,Potential for abuse and dependence: controlled substance (Schedule IV)
Hypersensitivity to levetiracetam or any component of Spritam
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation of an MAOI,Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs) due to risk of serotonin syndrome,Hypersensitivity to fenfluramine or any component of the formulation
No significant food interactions. SPRITAM can be taken with or without food. A high-fat meal may slightly delay absorption but does not affect overall exposure. Avoid grapefruit juice? Not required; no known interaction with grapefruit. Alcohol may potentiate CNS depression and should be avoided.
Avoid grapefruit and grapefruit juice as they are CYP1A2 inhibitors and may increase fenfluramine exposure. No other significant food interactions reported.
Spritam (levetiracetam) is classified as Pregnancy Category C. In the first trimester, there is an increased risk of major congenital malformations, including neural tube defects, when used in polytherapy, but monotherapy may have a lower risk. Data from human pregnancy registries suggest a risk of major birth defects of 1.5-2.4% with monotherapy, compared to a baseline risk of 2-4%. In the second and third trimesters, exposure may lead to decreased fetal growth and transient neonatal effects such as sedation, withdrawal symptoms, and hypotonia. Levetiracetam is not highly protein-bound and crosses the placenta with a cord-to-maternal plasma ratio close to 1.
FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In animal studies, fenfluramine caused embryofetal mortality and structural abnormalities at clinically relevant doses. During the second and third trimesters, exposure may lead to fetal growth restriction and neurodevelopmental effects. Use during pregnancy is contraindicated unless no safer alternative exists.
Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is about 1-3% of maternal weight-adjusted dose, which is considered low. Limited data suggest no adverse effects on infant development. However, due to potential for lethargy and poor feeding, breastfeeding should be monitored. The benefits of breastfeeding likely outweigh risks for most infants.
Fenfluramine is excreted into human breast milk; the milk-to-plasma (M/P) ratio is approximately 0.5. Based on limited data, the relative infant dose is estimated to be <10% of the maternal weight-adjusted dose. However, prolonged exposure may cause adverse effects in the infant (e.g., irritability, feeding difficulties). Breastfeeding is not recommended during FINTEPLA therapy due to potential for serious adverse reactions.
Pregnancy can alter levetiracetam pharmacokinetics, with increased clearance and reduced serum concentrations in the second and third trimesters. Dose adjustments may be necessary to maintain seizure control. Therapeutic drug monitoring is recommended, with target trough levels at the lower end of the therapeutic range (12-46 mcg/m L) to minimize fetal exposure while ensuring efficacy. Postpartum, clearance returns to baseline, and doses should be reduced accordingly.
No specific dose adjustments are recommended for pregnancy due to lack of pharmacokinetic studies. However, physiological changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may necessitate therapeutic drug monitoring and dose titration. Use lowest effective dose and consider alternative agents if possible.
SPRITAM (levetiracetam) is a racetam anticonvulsant with a unique mechanism of action (SV2A binding). It exhibits linear pharmacokinetics with rapid oral absorption. No therapeutic drug monitoring required due to wide therapeutic index. Adjust dose in renal impairment (Cr Cl <80 m L/min). Free fraction of levetiracetam is not affected by hepatic impairment. Titrate slowly to reduce CNS side effects (somnolence, dizziness). Abrupt discontinuation may increase seizure frequency. Available in immediate-release tablets.
FINTEPLA (fenfluramine) is indicated for seizures associated with Dravet syndrome. Monitor for valvular heart disease and pulmonary arterial hypertension due to serotonergic effects; obtain baseline and periodic echocardiograms. Titrate slowly to minimize appetite suppression and weight loss. Avoid concurrent use with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs due to risk of serotonin syndrome. Dose adjustment required in hepatic impairment.
Take SPRITAM exactly as prescribed; do not stop suddenly.,May cause dizziness or drowsiness; avoid driving until effects are known.,Monitor for mood changes, depression, or suicidal thoughts.,Report any skin rash or signs of allergic reaction immediately.,Use reliable contraception if applicable (no known major interaction with hormonal contraceptives).,Swallow tablets whole; do not crush or chew.,Store at room temperature, away from moisture.
Take exactly as prescribed; do not stop abruptly as withdrawal may increase seizure frequency.,Common side effects include decreased appetite, weight loss, diarrhea, and fatigue.,Report any signs of heart problems such as shortness of breath, chest pain, or swelling of ankles.,Avoid grapefruit and grapefruit juice during treatment as it may increase drug levels.,Women of childbearing potential should use effective contraception due to potential fetal harm.,Do not drive or operate heavy machinery until you know how the medication affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRITAM vs FINTEPLA, answered by our medical review team.
SPRITAM is a Antiepileptic that works by Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.. FINTEPLA is a Antiepileptic that works by Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRITAM and FINTEPLA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRITAM is: SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.. The standard adult dose of FINTEPLA is: 0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRITAM and FINTEPLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRITAM is classified as Category C. Spritam (levetiracetam) is classified as Pregnancy Category C. In the first trimester, there is an increased risk of major congenital malformations, including neural tube defects, . FINTEPLA is classified as Category C. FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In ani. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.